Member Info for olderbutwiser

Well the sp went exponential in the last hour of trading yesterday so the correction this morning not too surprising.
I think has stabilised and this will gain strength and should resume rising again either later today or over the rest of the week.
The placing was only for 5% and shares were all already placed with existing and new investors at the time of the placing RNS .
The company is certainly at such a crazy low price for all the potential it has.
Agree with others that any one of the many potential news events will propel this skywards
GLA.

Just to clarify my previous post for the newbies.
When I said NXP002 treats covid-19 I meant it treats lung issues caused by covid-19 (and it could well treat covid heart issues as well based upon recent scientific reports).
Important difference.

News is well overdue for NXP002 deal.
The potential here has grown with the covid-19 application of nxp002.
The placing I saw as a positive to quickly fund the additional covid-19 pre-clinical trials to test NXP002 in combination with standard treatments. - already implies that nxp002 on its own is seen as a good treatment for covid-19.
Covid-19 just happens to be a type of ARDS lung issue and Nuformixc have had an outstanding treatment available for that for some time - just waiting for the first deal. Company already stated that there is increased interest due to covid aspect.
I certainly think there is huge potential here.
So it could happen any day I am just waiting for the fabled RNS.
GLA

This looks and feels a bit like a pump and dump, started by the 3 largish trades late yesterday morning all within a few minutes.
Happy if it is not, but not holding much hope.

The anti-vax lobby is growing and they will point to the rush to get out a vaccine and potential for safety issues.
The chinese and russians also have vaccines and are inoculating ! HHmmmm
Well it will be interesting to see what percentage of population get the vaccine, especially in the US!
Seem to recall BBC or somewhere did a poll of who would get the vaccine and quite a high percentage said they would not.

Agree it would be nice to have CEO sooner rather than later.
BUT
Give Chris Blackwell a chance – it is only 7 working days since the placing announcement!
Things probably already be under way with most aspects mentioned in the placing RNS and Chris probably had a person/ persons in mind.
I feel more progress has been made in the last 3 months since Chris Blackwell was at the helm, than in the previous year with DT and DG on the BOD. So I am quite happy for Chris to carry on for the time being.
‘Expanding the company’s business development personnel will optimise the chances of securing additional deals.’ - does not necessarily preclude a deal happening before those personnel have their feet under the desk – although extra hands to handle the workload always helpful.
We are all frustrated as hell.
Agree with your comment Kit.Sharma - Let's hope we are not too far away with some positive news for us all.
Have a good weekend all!

For "impartiality" I should say "normal protocol".

That many of the so-called treatments and their associated trials for covid-19 must now be considered questionable. The need to try to respond rapidly earlier this year may possibly have affected scientific judgement and impartiality.
The world needs a cost effect treatment, not a new cutting edge treatment with its usually high cost.
Using an existing known drug that has recently been improved is a good approach. Cost effective, faster to develop, plus lots of other benefits. Well I think you know what comes next………..

From BBC today.
"For its Solidarity clinical trial, the WHO tested the effects four potential treatments - remdesivir, an Ebola drug, was one, but they also looked at malaria drug hydroxychloroquine, interferon, and the HIV drug combination of lopinavir and ritonavir.
The drugs were tested with 11,266 adult patients in total, across 500 hospitals in more than 30 different countries.
The results, which are yet to be reviewed, suggest that none of these treatments has a substantial effect on mortality or on the length of time spent in hospital, the WHO said on Thursday.
WHO chief scientist Soumya Swaminathan said on Wednesday that their trials on hydroxychloroquine and lopinavir/ritonavir were stopped in June because they had already proven ineffective. However, the other trials continued.

There is a bit of uncertainty in the data, but the study says it "absolutely excludes" the idea remdesivir can save a significant number of lives and says the findings are "comfortably compatible" with the drug having no life-saving effect at all. It is a similar message for preventing people needing ventilation or speeding up people's recovery.
So far, doctors have been raiding the cupboard for existing drugs that can fight coronavirus.
The results have been disappointing with malaria drugs, HIV drugs, MS drugs and now an Ebola drug (remdesivir). Only an old steroid - dexamethasone - has proven life-saving.
The attention is now turning to new experimental therapies such as antibodies designed in the lab to fight the virus and new, untested, anti-viral drugs.
We are still waiting for the results of these trials, but the worry is "new" in medicine tends to mean "expensive", and that will raise questions about who gets to have them."

https://www.bbc.co.uk/news/world-54566730

Seems there is still plenty of scope to be a drug for treating covid-19 and its after-effects – now wonder where they could try?!.

The 'vanilla' Tranilast as you call it has a number of significant problems - NXP002 has overcome many of these problems in its patented cocrystal formulation.
Tranilast is out of patent whereas NXP002 has a new patent covering its use.

The BBC link from earlier today https://www.bbc.co.uk/news/health-54540544 talks about both lung and heart damage in long-covid.

The research article below, dated 24the September 2020, says Tranilast (NXP002) able to treat both lung and heart aspects through its action on the NLRP3 pathway.
https://www.google.com/url?sa=t&source=web&rct=j&url=https://www.europeanreview.org/wp/wp-content/uploads/9169-9171.pdf&ved=2ahUKEwj71oyEvqjsAhUuaRUIHaVMCJsQFjABegQICRAH&usg=AOvVaw1fKMmF788gR4mDr0MkHFot

We are positioned with drugs able to treat ARDS and covid-19. I think people will soon wake up to the potential here. I am sure that potential partners have already woken up to what Nuformix have to offer.

From the RNS on 22 July:
‘NXP002 is our anti-fibrotic product and is one of those products that we have with the potential to help in the treatment of covid-19 although this still needs some clinical validation.’
From the Proactive video on 22 July Chris says:
‘There are advantages for companies that are hitting the sweet-spot at the moment, which of course is looking at covid-19, and as I think I have mentioned phenomenal opportunities which we want to investigate and potentially pursue for that.’

Seems that over the last couple of months they have investigated further this ‘phenomenal opportunity’ and it looks even better so now they are going all out to pursue it.

For me, one of the unsaid but implicit aspects of the last RNS is that for Nuformix to even consider undertaking additional pre-clinical work studying the benefit of NXP002 in combination with existing therapies , they must have already seen significant benefit just from using NXP002 on its own, otherwise such work would not be worthwhile. Tells me they are confident of NXP002's efficacy.

Using drug combinations to treat ARDS/ covid-19 seems to be an important aspect to allow widespread clinical use. So by showing that NXP002 can be used in combination with other existing IPF drugs then it can provide a more effective treatment, have greater clinical application, will be easier to use by doctors and therefore has significantly greater commercial value.

This sentence in the 22 July RNS is starting to feel more credible now.

'during this time, the interest in our assets and their potential in the treatment of COVID-19, as well as the resultant fibrosis, has increased. These business discussions are confidential and further announcements will be made as and when appropriate.'

I am feeling a bit more positive about an RNS to announce positive preliminary results, or advanced discussions, or even a deal in the near future.

Covid-19 is now known to be one of the various causes of ARDS.
Acute respiratory distress syndrome (ARDS) is a type of respiratory failure characterized by rapid onset of widespread inflammation in the lungs.
Many patients with ARDS survive the acute phase, but subsequently go on to die, often with evidence of significant lung scarring and damage (pulmonary fibrosis).
NXP002 potentially prevents or treats the condition.
Covid-19 lung inflammation occurs extremely quickly but nxp002 targets the same NLRP3 pathway to damp down the inflammatory mechanism.
So its use for ARDS/ IPF or Covid-19 lung are essentially the same – albeit from a different root cause.
I certainly agree that Nuformix is at very early stages with NXP002 and NXP004 and have limited resources and cannot possibly go after every possible indication.
The cardio potential of Tranilast is for someone else to pursue.
But since we have patents on NXP002 (a superior form of Tranilast) then we could out-license NXP002 for those other indications, much like the Oxilio option.
It also adds to the general interest in the NLRP3 inflammasome, Nuformix and the potential value of its patents.

The link from Kit.Sharma is fascinating.
It was only released on 24/09/2020, so very new data.

"Abstract. – NLRP3 inflammasome has recently become an intriguing target of several chronic and viral diseases. Here, we argue that targeting NLRP3 inflammasome could be a strategy to prevent cardiovascular outcomes [fulminant myocarditis, heart failure, venous thoromboembolism (VTE)] and acute respiratory distress syndrome (ARDS) in patients with SARSCoV-2 infection. We discuss the rational for NLRP3 targeting in clinical trials as an effective therapeutic strategy aimed to improve prognosis of COVID-19, analyzing the potential of two therapeutic options (tranilast and OLT1177) currently available in clinical practice."

So not only confirms what we knew but that we now possibly have additional potential for NXP002 (or NXP004?) to also be used to prevent cardiovascular outcomes [fulminant myocarditis, heart failure, venous thromboembolism (VTE)] as well as the lung treatment.
This cold and wet Saturday just got a lot better.
Don't normally look in on weekend but glad I did now.

The link from Kit.Sharma is fascinating.
It was only released on 24/09/2020, so very new data.
Abstract. – NLRP3 inflammasome has recently become an intriguing target of several chronic and viral diseases. Here, we argue that targeting NLRP3 inflammasome could be a strategy to prevent cardiovascular outcomes [fulminant myocarditis, heart failure, venous thoromboembolism (VTE)] and acute respiratory distress syndrome (ARDS) in patients with SARSCoV-2 infection. We discuss the rational for NLRP3 targeting in clinical trials as an effective therapeutic strategy aimed to improve prognosis of COVID-19, analyzing the potential of two therapeutic options (tranilast and OLT1177) currently available in clinical practice.
So we now possibly have additional potential for NXP002 (or NXP004?) to also be used to prevent cardiovascular outcomes [fulminant myocarditis, heart failure, venous thoromboembolism (VTE)] as well as the lung treatment.
It could just be getting better and better.

Offshoresailor - It may be that I am mis-reading your post but I view things with a slightly different emphasis.
The placing is primarily for the additional development of the assets to treat covid-19 and the company needs a few more hands to do that, and especially to do that quickly.
o To strengthen the data packages to include, identify and protect the covid-19 aspects.
o Further evaluate the assets for treating covid-19 and in combination with other treatments.
o Increase the company headcount to provide additional business development resources to secure deals for nxp002 for IPF and covid-19.
Obviously they have needed a new CEO asap, anyway. There will obviously be some overlap between the additional work for covid-19 and what was already planned just for the NXP002 IPF applications.
This additional development work for covid-19 is potentially Nuformix’s key to unlocking the IPF/ ARDS market and makes NXP002 so much more attractive commercially and of interest to potential partners to move quickly – and perhaps put a rocket up the backside of whoever we have been in negotiations with for so long (Kissei?).

Hi Kit.Sharma
Really interesting article .
Seems to be very recent at 24th Sept 2020 .
Good find.

'That is almost certainly not the case' - should read - 'That does not follow'.
I meant to change it before sending. Am on train with smartphone but dumb user and LSE message box scroll is rather frustrating.
Apologies

ForFXSake - "The fact that they have done a placing now means that they are not expecting any big deals with chunky up-front payments to land in the very near term (otherwise they wouldn't need the money)."
That is almost certainly not the case.
Directors should not gamble on deals coming in, too risky.
They needed the placing primarily to fund the accelerated covid-19 work and related business development.
With a placing you know you have the cash available, whereas even if you are pretty sure you will get a deal soon, it may be delayed for any number of reasons, as we know only too well, don’t we Dan!
Also by knowing the funding was going to be available through the placing the BOD could already have kicked off the covid-19 activities, either preparing or even starting pre-clinical work.
So a potential advantage of the placing is to get things moving faster.

Jay12 - Ob good news is what we need.
Well the first seven months of 2020 were absolutely pants, but since then we have had the following good news:
• Excellent trial results. for NXP004 - potential really promising .
• Oxilio option deal - guaranteed option payment and hopefully deal to follow - new addition to portfolio.
• Nxp002 use for Covid-19 being accelerated - with negotiations almost certainly underway.
What we actually want is continued good news flow and the hoped for deals to now come in to overcome the **** from the first half of the year and generate confidence in the management, future and sp of the company.
It is looking promising.
Here's hoping.